Daily Piece: FDA Gives Green Light on First Interoperable Insulin Pump

FDA gave a great Valentines gift for those living with diabetes on insulin pump therapy…the green light on Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2). It is also referred to as an alternate controller enabled (ACE) infusion pump, or ACE insulin pump. It can be used with different components that make up diabetes therapy systems, allowing patients to tailor their diabetes management to their individual device preferences.  To learn more click below.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm631412.htm

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#FDA #Tandem #interoperable #insulin #pump

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Low Diabetes Exam Frequency in U.S.

I have recently written a manuscript on a quality improvement project focused on increasing frequency of documented diabetes eye exam in EMR system for an internal and family medicine practice. So naturally, the article, “Diabetes Eye Exam Frequency in US is ‘Alarmingly Low,'” on Medscape Medical News caught my eye. Dr. Benoit with Centers for Diabetes Control completed an analysis of claims data for insured persons with type 2 diabetes (300,000) with no retinopathy at baseline, and type 1 diabetes (3000). For those with type 2 diabetes in this analysis, only about one in seven met the American Diabetes Association (ADA)’s recommendation for annual or biennial exam. For those with type 1 diabetes, only a quarter met the ADA recommendation. Remember this analysis reflects insured not uninsured persons. To learn more, please click below.

https://www.medscape.com/viewarticle/908973

Diabetes Eye Exam Frequency in US Is ‘Alarmingly Low’ – Medscape – Feb 12, 2019.

Image result for diabetes eye exam
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#diabetes #eye #exam #U.S.

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Immunizations Matter

As I was reading my Pharmacy Today from American Pharmacists Association this morning, the headlines of “CDC: influenza activity has highest level this season,” and “In measles outbreak, demand for vaccine spikes” caught my attention. Later in day, a question arose about catch up immunization schedule for polio vaccine in a young adult. To have creditability, I can confidently say that I am up to date with all of my vaccines. Vaccines truly matter as evidenced by the recent measles outbreak. Are you uncertain as to whether you or kids are up to date on your immunizations? If not, click below on link to CDC for vaccination details.

https://www.cdc.gov/vaccines/parents/index.html

https://www.cdc.gov/vaccines/adults/index.html

https://www.cdc.gov/vaccines/pregnancy/index.html

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#immunizations #matter #disease #prevention

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Innovative Insulin Delivery Research

Innovation is vital in transforming all aspects of our life. For those with living with diabetes, the recent innovation of delivering insulin via a specialized pill injection from a MIT research is of great interest. It utilizes self-orienting millimeter scale application (SOMA). The capsule contains a small needle that is made up of solid, compressed insulin. The ingested insulin is injected into the stomach wall which is pain less. To learn more please click below.

https://www.news-medical.net/news/20190207/Insulin-in-a-pill-from-MIT-researchers.aspx

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#insulin #delivery #innovation

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Transforming Complications Conversation

Prior to reading an article by Renza and Chris (they live with diabetes so they have full creditability) in BMJ, I thought that I was doing great when I shared “you do not have to have complications from diabetes, they are preventable” to a person with newly diagnosed diabetes. I assumed that this statement would empower the person with diabetes. Well, as it turns out this language is not so helpful. Implying that complications are preventable can create a sense of blame in the person with diabetes if they develop complications. Reframing the conversation so focus is on reducing complications which creates opportunity for person to share more freely and openly without feeling judged. Shift the focus from prevention of complications to daily care. As a diabetes educator, I have committed to transform my conversations with persons with diabetes. Will you join me this commitment?

https://www.bmj.com/content/364/bmj.k5258

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#reframe #complications #daily #care

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: New Feature, IQcast, for Guardian Connect CGM Users Paired with Sugar.IQ app

Exciting news for Guardian Connect CGM users in the US who are paired with Sugar.IQ app as they now have a new hypoglycemia prediction feature, IQcast. This feature provides users notification if low event is predicted to occur within next 1 – 4 hours.

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#IQcast #Sugar.IQ #Medtronic

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Much news over the last couple of years with regards to SGLT2 inhibitors and cardiovascular outcomes from studies has been highlighted. A study of dapagliflozin and its impact on cardiovascular outcomes in 17,160 patients with Type 2 diabetes (who had or were at risk for atherosclerotic cardiovascular disease) who were followed for a median of 4.2 years. Specifically, patients were randomly assigned to receive receive either dapagliflozin or placebo.  The primary efficacy outcomes were major adverse cardiovascular events (MACE) (cardiovascular death, myocardial infarction, or ischemic stroke) and a composite of cardiovascular death or hospitalization for heart failure. The primary safety outcome was a composite of MACE. Treatment with dapagliflozin resulted in a lower rate of cardiovascular death or hospitalization for heart failure which reflects a lower rate of hospitalization for heart failure. However, treatment with dapagliflozin did not result in a higher or lower rate of MACE as compared to placebo. To learn more, please click below.

https://www.nejm.org/doi/full/10.1056/NEJMoa1812389

Image result for dapagliflozin
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#dapagliflozin #cardiovascular #outcomes

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Randomized Trial Shows Oral Insulin Feasibility

A current first ever randomized trial of oral insulin use in persons with Type 2 diabetes shows feasibility. This trial which is sponsored by NovoNordisk has been discontinued yet it shows promise for the future studies of oral insulin. To learn more, please click below.

https://www.medscape.com/viewarticle/908204

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#oral #insulin #trial

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Zynquista, SGLT 1/2 Inhibitor, for Type 1 Diabetes

FDA advisory committee recently voted on a new SGLT 1/2 inhibitor, Zynquista, for Type 1 diabetes. If approved, this medication can be used with insulin which would decrease insulin doses and weight. It is a dual inhibitor pill that is taken once daily. It is being developed by Lexicon and Sanofi. STICH is proposed acronym for persons with Type 1 to take if ketones are high (while taking SGLT inhibitor).

STop SGLT inhibitor; Inject bolus insulin; Consume 30 grams of carbs; Hydrate (ideally with water)

What makes it particularly exciting is if approved Zynquista would be the first oral diabetes medication approved for use in Type 1 diabetes. Now that would be a game changer.

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#zynquista #dual #SGLT inhibitor

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Daily Piece: Physical Activity May Reduce Depression Symptoms

We know that physical activity improves our health and quality life. A recent study of adults with bipolar disease, major depressive disorder and those without history of mood disorders found that physical activity can be an effective target for strategies to change mood states. In this study, physical activity affected how energetic participants felt and how long they slept. To learn about this study, click below.

https://www.nih.gov/news-events/nih-research-matters/physical-activity-helps-reduce-depression-symptoms#.XD-aLdKHSD4.linkedin

Image result for physical activity and mood

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#physical #activity #mood

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.